Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy
| Status: | Recruiting |
|---|---|
| Conditions: | Infectious Disease, Hospital |
| Therapuetic Areas: | Immunology / Infectious Diseases, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 2/9/2019 |
| Start Date: | August 2015 |
| End Date: | April 2020 |
| Contact: | Joseph A Tyndall, MD |
| Email: | tyndall@ufl.edu |
| Phone: | 352-265-5911 |
Molecular Epidemiology and Phylodynamic and Phylogeographic Analysis of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Transmission: An Emergency Department Population Sampling Strategy
Given that the Emergency Department (ED) has become the entry way for large populations of
patients into the health care system, a strategy of sampling MRSA isolates in ED populations
and merging this information with patient-level data may present a window to hypothesize and
investigate CA-MRSA transmission within the community and its impact on hospital-acquired
infections.
patients into the health care system, a strategy of sampling MRSA isolates in ED populations
and merging this information with patient-level data may present a window to hypothesize and
investigate CA-MRSA transmission within the community and its impact on hospital-acquired
infections.
Prospective cross-sectional study involving 500 patients enrolled over a one year period at
the UFHealth Shands Hospital's Adult and Pediatric Emergency Department. The collected
information will serve as pilot data for a future large comprehensive multi-site study.
Patients will have a wound culture and a nasal swab obtained as part of the study, which will
be assessed for MRSA isolates using next-generation whole genome sequencing. The principal
investigator or PI designee will also survey participants and review hospital records.
the UFHealth Shands Hospital's Adult and Pediatric Emergency Department. The collected
information will serve as pilot data for a future large comprehensive multi-site study.
Patients will have a wound culture and a nasal swab obtained as part of the study, which will
be assessed for MRSA isolates using next-generation whole genome sequencing. The principal
investigator or PI designee will also survey participants and review hospital records.
Inclusion Criteria:
- Patient or Legally Authorized Representative (LAR) must have voluntarily signed an
Institutional Review Board-approved informed consent form before initiation of any
study procedures
- Patient presents with an acute abscess or a non-post-operative skin/soft tissue
infection
- Patient presents through the UFHealth Shands Emergency Department
Exclusion Criteria:
- Patients who are employed by UFHealth and provide direct patient care
- Patients who have previously been enrolled in the study
- Patients who are not suitable for the study in the opinion of the investigator
We found this trial at
1
site
Gainesville, Florida 32608
Principal Investigator: Joseph A Tyndall, MD
Phone: 352-265-5911
Click here to add this to my saved trials
